Treatment of hyponatraemia in patients with SIADH or CHF with intravenous conivaptan (YM087), a new combined vasopressin V1A/V2 receptor antagonist

被引：0
|
作者：
Abraham, W
Koren, M
Bichet, DG
Verbalis, JG
Klapholz, M
Selaru, P
Bakker-Arkema, RG
Rummel, SA
机构：
[1] Univ Cincinnati, Coll Med, Dept Cardiol, Cincinnati, OH USA
[2] Jacksonville Ctr Clin Res, Jacksonville, FL USA
[3] Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada
[4] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[5] Univ Med & Dent New Jersey, Newark, NJ 07103 USA
[6] Warner Lambert Co, Parke Davis Pharmaceut Res Div, Ann Arbor, MI USA
来源：
EUROPEAN HEART JOURNAL | 2000年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1848
引用
收藏
页码：345 / 345
页数：1
相关论文
共 50 条
  • [21] A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
    Wada, Koh-ichi
    Matsuyawa, Utane
    Fujimori, Akira
    Arai, Yukinori
    Sudoh, Katsumi
    Sasamata, Masao
    Miyata, Keiji
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2007, 30 (01) : 91 - 95
  • [22] Pharmacological characterization of YM471, a novel potent vasopressin V1A and V2 receptor antagonist
    Tsukuda, J
    Tahara, A
    Tomura, Y
    Wada, K
    Kusayama, T
    Ishii, N
    Aoki, M
    Yatsu, T
    Uchida, W
    Taniguchi, N
    Tanaka, A
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 446 (1-3) : 129 - 138
  • [23] Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V-1A and V-2 receptor antagonist, in vitro and in vivo
    Tahara, A
    Tomura, Y
    Wada, KI
    Kusayama, T
    Tsukada, J
    Takanashi, M
    Yatsu, T
    Uchida, W
    Tanaka, A
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1997, 282 (01): : 301 - 308
  • [24] Urinary water clearance after infusion of conivaptan, a combined vasopressin V1A and V2 receptor antagonist, in patients with NYHA class III/IV heart failure
    Painchaud, C
    Bichet, D
    Udelson, JE
    Ghazzi, MM
    Selaru, P
    Chartier, K
    EUROPEAN HEART JOURNAL, 2001, 22 : 394 - 394
  • [25] Urinary water clearance after infusion of conivaptan, a combined vasopressin V1a and V2 receptor antagonist, in patients with NYHA class III/IV heart failure
    Painchaud, CA
    Ghazzi, MM
    Selaru, P
    Bichet, DG
    Chartier, KK
    Udelson, JE
    CIRCULATION, 2000, 102 (18) : 535 - 535
  • [26] Vascular Effects of RWJ-676070, a Selective Combined V1a/V2 Vasopressin Receptor Antagonist
    Coltamai, L.
    Bucher, M.
    Maillard, M. P.
    Shukla, U.
    Bohidar, N.
    Haskell, L.
    Bertelsen, K.
    Fedgchin, M.
    Vogt, B.
    Burnier, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (02) : 145 - 148
  • [27] Novel vasopressin V1A and V2 antagonist (Conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia
    Verbalis, JG
    Bisaha, JG
    Smith, N
    CIRCULATION, 2004, 110 (17) : 723 - 723
  • [28] Novel vasopressin V1A and V2 antagonist (conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia
    Verbalis, JG
    Bisaha, JG
    Smith, N
    JOURNAL OF CARDIAC FAILURE, 2004, 10 (04) : S27 - S27
  • [29] Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists?
    Goldsmith, Steven R.
    AMERICAN JOURNAL OF MEDICINE, 2006, 119 : S93 - S96
  • [30] TREATMENT WITH THE V1A/V2-VASOPRESSIN RECEPTOR ANTAGONIST CONIVAPTAN INCREASES CARDIAC OUTPUT DURING EXERCISE IN PATIENTS WITH ADVANCED HEART FAILURE
    Balling, Louise
    Thomsen, Jakob H.
    Wolsk, Emil
    Hassager, Christian
    Boesgaard, Soeren
    Goldsmith, Steven
    Gustafsson, Finn
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 1319 - 1319
12345